Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
View More
Community Practice Connections™: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
View More
4th annual Precision Medicine Symposium: An Illustrated Tumor Board
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
View More
Pembrolizumab Plus Enzalutamide and ADT Falls Short in mHSPC
Pembrolizumab, in addition to enzalutamide and androgen deprivation therapy, was not associated with better radiographic progression-free survival outcomes in patients with metastatic hormone-sensitive prostate cancer.
Patients With Prostate Cancer Report Better Quality of Life With 18 Months of ADT vs 36 Months
November 23rd 2023Patients with prostate cancer who received 18 months of androgen deprivation therapy were more likely to recover their serum testosterone levels and to recover quicker than those who received 36 months of therapy.
New Companion Diagnostic Is Approved to Aid In Gastric Cancer Decision Making
The PD-L1 IHC 22C3 pharmDx diagnostic tool will help identify patients with gastric or gastroesophageal junction adenocarcinoma whose disease expresses PD-L1 and who are thereby eligible for pembrolizumab.